|
|
Eyeing the Options for Treating Meibomian Gland Dysfunction and Dry Eye Disease
Dry eye disease (DED) is highly prevalent but frequently underdiagnosed and subsequently undertreated. Studies have demonstrated that meibomian gland dysfunction (MGD) is a leading cause of the development and progression of evaporative DED, caused by a deficient tear film lipid layer that leads to increased tear evaporation. New and emerging treatments with novel mechanisms of action are being investigated that manage the signs and symptoms of DED associated with MGD and offer the potential f... |
|
|
Recognition and Referral: Best Practices for Managing Patients with GA
Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ... |
|